“DOSE OF REALITY” | Calling Big Pharma’s Bluff On PBMs: Part V

Big Pharma has tried to evade culpability for the crisis of rising prescription drug prices by pointing a finger at pharmacy benefit managers (PBMs).  As the U.S. Senate Committee on Finance prepares to hear from the executives of five PBMs on April 9, it’s time to debunk Big Pharma’s bluffs.  PBMs serve an essential role in the prescription drug distribution chain and work on behalf of payers and consumers to reduce prescription drug costs, increase convenience and improve safety.

Ahead of the hearing, we’re setting the record straight on the essential role PBMs play in negotiating savings for patients by calling out Big Pharma’s suspect claims and pushing back on the proposed Rebate Rule’s false promises.

Yesterday, we dismantled the argument that eliminating rebates would benefit Medicare seniors.

In our final installment, we beat back on the premise that banning rebates would be anything other than a win for Big Pharma.


Banning Rebates Wouldn’t Reward Big Pharma For Price Gouging.


By The Government’s Own Analysis, The Rebate Rule Would Line Big Pharma’s Pockets With A $137 Billion Giveaway And “The Pharmaceutical Manufacturers Would Benefit From The Proposed Rule Overall.” 

Actuarial Analysis Concludes “The Costs [Of The Rebate Rule] To The Federal Government Would More Than Offset … Savings.”  

Concerns Around The Rebate Rules’ Uncertainty And Its Potential To Put More Power In The Hands Of Big Pharma Are Shared By Health Care Experts, Industry Organizations And Journalists.  


Click through to catch up on Calling Big Pharma’s Bluff On PBMs: Part I HERE, Part II HERE, Part III HERE and Part IV HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.